ABSTRACT
Considerable interannual variation in the abundance of larval and juvenile Pacific herring Clupea pallasii was detected in Miyako Bay, on the Pacific coast of northern Japan; abundances were high in 2001 and 2003 and low in 2000 and 2002. Hatch dates and growth rates for larval and juvenile survivors were estimated through otolith analysis. Water temperature and food availability were monitored on the spawning and nursery grounds in the inner part of the bay. The number of spawning females caught in nets set around the spawning ground was recorded during each spawning season (January to May) in 2000-2003. No correlation was found between the number of spawning females and the abundance of larvae and juveniles on the spawning and nursery grounds. The hatch dates of surviving larvae and juveniles were concentrated at the end of the spawning season in 2001 and in the middle of the season in 2003. The larvae experienced relatively high prey concentrations during the first-feeding period in 2001 but low concentrations in 2003. Survival of larvae during the first-feeding period may be a function of prey concentration as well as water temperature. In 2003, low water temperature would reduce starvation mortality during the first-feeding period. In contrast, unfavourable feeding conditions with higher temperatures during the first-feeding period seemed to result in low larval survival in 2000 and 2002. The 2001 larvae grew faster than those in 2003 because of the late hatch dates and the higher ambient temperatures that resulted. Temperature might be a major factor controlling growth rates of C. pallasii larvae in Miyako Bay.
Subject(s)
Fishes/growth & development , Animals , Ecosystem , Female , Japan , Larva/growth & development , Temperature , ZooplanktonSubject(s)
Adaptor Proteins, Signal Transducing/metabolism , Carrier Proteins/metabolism , Genes , Receptor, Insulin/metabolism , Actin Cytoskeleton/metabolism , Adaptor Proteins, Signal Transducing/genetics , Animals , Carrier Proteins/genetics , Cell Membrane/drug effects , Cells, Cultured , Endothelial Cells/metabolism , Endothelium, Vascular/cytology , Fluorescein-5-isothiocyanate/metabolism , Fluorescent Antibody Technique, Direct , Fluorescent Dyes/metabolism , Humans , Mice , NIH 3T3 Cells , Plasmids , Platelet-Derived Growth Factor/pharmacology , Precipitin Tests , Protein Binding/genetics , Time Factors , Transfection , Umbilical Veins/cytologySubject(s)
Cord Blood Stem Cell Transplantation/adverse effects , Exanthema/virology , Herpesviridae Infections/diagnosis , Herpesviridae Infections/pathology , Herpesvirus 6, Human/genetics , Liver Diseases/virology , Antigens, CD34/biosynthesis , Bone Marrow Transplantation , Female , Fever , Humans , Leukemia/therapy , Lung/pathology , Middle Aged , Myelodysplastic Syndromes/therapy , Time Factors , Transplantation ConditioningABSTRACT
Many patients suffer febrile diseases soon after allogeneic stem cell transplantation (SCT). Some of the symptoms of viral infections and acute GVHD are often difficult to distinguish. However, an accurate diagnosis is important since the treatments for these conditions are different. It is known that MxA protein is specifically induced in patients with several viral infections. We investigated the cytoplasmic expression of MxA in the peripheral blood mononuclear cells (PBMCs) of patients with fever after allogeneic SCT using a newly generated monoclonal antibody (KM1135) and flow cytometry. The level of MxA expression was significantly higher in patients diagnosed with viral infections (n=6, cytomegalovirus in three, Epstein-Barr virus in one, human herpesvirus-6 in one, adenovirus in one) than control individuals (n=9) (P<0.05, Mann-Whitney test). The level of MxA in patients with aGVHD (n=7) was identical to that in controls. The level of MxA correlated well with the amount of the cytomegalovirus antigen-positive cells in the presence of acute GVHD in two patients. The measurement of MxA is simple and useful in distinguishing viral disease from acute GVHD after allogeneic SCT.
Subject(s)
GTP-Binding Proteins/analysis , Hematopoietic Stem Cell Transplantation/adverse effects , Virus Diseases/diagnosis , Adolescent , Adult , Antibodies, Monoclonal , Case-Control Studies , Child , Diagnosis, Differential , Female , Fever/etiology , Flow Cytometry , Graft vs Host Disease/diagnosis , Humans , Leukocytes, Mononuclear/chemistry , Male , Middle Aged , Myxovirus Resistance Proteins , Transplantation, Homologous , Virus Diseases/etiologyABSTRACT
Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. We describe here a patient who developed ADEM after allogeneic bone marrow transplantation (BMT). A 48-year-old woman with acute myeloid leukemia (M2) underwent allogeneic BMT from her HLA-identical sister. Cyclosporin for prophylaxis of acute graft-versus-host disease (GVHD) was discontinued from day 15 because of its toxicity. She was relatively well after the resolution of cytomegalovirus reactivation and chronic GVHD. Nine months after BMT, she suddenly developed diplopia, dysarthria, and gait disturbance. Computed tomography of the brain at that time revealed no abnormal findings. Leukemia recurrence was not revealed. The neurological symptoms were very mild without further deterioration. Her clinical course was carefully watched without therapy. Two weeks after onset, fluid attenuated inversion recovery magnetic resonance imaging (MRI) revealed multifocal abnormal high-signal intensity mainly in the white matter of the cerebrum as well as in the cerebellum and brainstem. Cerebrospinal fluid examination showed no abnormal findings. No laboratory findings suggested the presence of infectious agents. The typical MRI findings and an acute monophasic clinical course of this patient led to a diagnosis of ADEM. Twelve weeks after onset, the symptoms had almost resolved. Follow-up MRI showed a substantial improvement of the previous lesions without any new lesions. The symptoms had completely resolved 5 months after onset. This is a rare case of ADEM developing after allogeneic BMT.
Subject(s)
Bone Marrow Transplantation/adverse effects , Encephalomyelitis, Acute Disseminated/etiology , Leukemia, Myeloid, Acute/therapy , Acute Disease , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/etiology , Cytomegalovirus Infections/pathology , Encephalomyelitis, Acute Disseminated/diagnosis , Female , Graft vs Host Disease/microbiology , Humans , Leukemia, Myeloid/complications , Leukemia, Myeloid/therapy , Leukemia, Myeloid, Acute/complications , Magnetic Resonance Imaging , Middle Aged , Transplantation, Homologous/adverse effectsABSTRACT
Autoimmune thrombocytopenia (AITP) after bone marrow transplantation (BMT) was suggested to occur by immune dysregulation mainly in association with graft-versus-host disease (GVHD). Here we present a patient who developed severe AITP after BMT. A 40-year-old woman with severe aplastic anemia received a BMT from a partially HLA-matched brother. Despite myeloid and erythroid engraftments, platelet recovery was delayed. All bone marrow cells were 46,XY and were derived from the donor. Grade I acute GVHD involving skin developed from day 34 posttransplantation, but promptly responded to prednisolone in addition to a prophylactic dose of tacrolimus. With the tapering of prednisolone, thrombocytopenia progressed without substantial changes in the white blood cell count, hemoglobin concentration, or reticulocyte count. On day 188, the patient developed chronic GVHD involving skin and liver, which promptly responded to the readministration of prednisolone and increased tacrolimus. However, the patient's platelet count decreased to 9 x 10(9) cells/L on day 222. The platelet-associated immunoglobulin G (PAIgG) values were elevated. Bone marrow examination showed hypercellularity with plentiful megakaryocytes. The number of colony-forming units-megakaryocyte was within the normal range. The elevated PAIgG values and a correlation between thrombocytopenia and the intensity of the immunosuppressive agents strongly suggested a causative role of the autoimmune mechanisms for thrombocytopenia in this patient.
Subject(s)
Anemia, Aplastic/therapy , Bone Marrow Transplantation/adverse effects , Purpura, Thrombocytopenic, Idiopathic/etiology , Adult , Anemia, Aplastic/complications , Bone Marrow Transplantation/immunology , Female , Graft vs Host Disease/immunology , Humans , Transplantation, Homologous/adverse effects , Transplantation, Homologous/immunologyABSTRACT
Seven adult patients with myelodysplastic syndrome (MDS)-related secondary acute myeloid leukaemia (AML) were treated with total body irradiation (TBI), cytosine arabinoside (Ara-C) and cyclophosphamide (CY), followed by unrelated human leucocyte antigen (HLA)-mismatched cord blood transplantation (CBT). Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C. Five patients are alive and free of disease at 7-31 months after transplantation. These preliminary results suggest that adult MDS-related secondary AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.
Subject(s)
Fetal Blood , Hematopoietic Stem Cell Transplantation/methods , Leukemia, Myeloid/complications , Leukemia, Myeloid/surgery , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/surgery , Acute Disease , Adult , Antimetabolites, Antineoplastic/therapeutic use , Cytarabine/therapeutic use , Female , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Transplantation/mortality , Humans , Leukemia, Myeloid/mortality , Male , Middle Aged , Myelodysplastic Syndromes/mortality , Prospective Studies , Survival Rate , Transplantation, Homologous , Whole-Body IrradiationABSTRACT
By using a conventional two-hybrid technique with an Src homology 3 (SH3) domain of Nesh as the bait protein, a novel full-length cDNA was isolated and sequenced from a human placenta cDNA library. This cDNA consists of 3023 bp and has a predicted open reading frame that encodes 486 amino acids. It possesses an SH3 binding motif, a nuclear targeting sequence, and no catalytic domain. Overall, it has no similarity to known molecules involved in a signaling cascade. Polymerase Chair reaction-based mapping with both a monochromosomal hybrid panel and radiation hybrid cell panels localized the gene on human chromosome 3q12 near the marker D3S1271.
Subject(s)
Carrier Proteins/genetics , Chromosomes, Human, Pair 3 , src Homology Domains , Amino Acid Sequence , Base Pairing , Base Sequence , Cloning, Molecular , Exons , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Two-Hybrid System Techniques , src Homology Domains/geneticsABSTRACT
p73, a homologue of p53 gene, is expressed in several normal tissues including central nervous system, but data regarding tumors are scant. In this study, we have analyzed the status and expression of the p73 gene in primary breast tumors, as well as 4 normal salivary glands, 2 carcinomas with metaplasia and mixed tumors. We found that periductal myoepithelial cells of all of the mammary gland examined were clearly stained with the specific anti-p73 antibody. Furthermore, we found the expression of p73 in the neoplastic myoepithelial cells in carcinomas with metaplasia and in mixed tumors. The findings in the present study provide valuable information on the characteristics of myoepithelial cells.
Subject(s)
Breast Neoplasms/pathology , DNA-Binding Proteins/genetics , Epithelial Cells/metabolism , Nuclear Proteins/genetics , Breast/chemistry , Breast/metabolism , Breast/pathology , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , DNA-Binding Proteins/analysis , Epithelial Cells/chemistry , Gene Expression Regulation, Neoplastic , Genes, Tumor Suppressor , Humans , Immunohistochemistry , Metaplasia , Nuclear Proteins/analysis , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Tumor Protein p73 , Tumor Suppressor ProteinsABSTRACT
The purpose of this study is to confirm the diagnosis of acute cerebral infarction on diffusion-weighted imaging using low field (0.2 T) magnetic resonance image(MRI). Acute cerebral infarctions in 51 patients were examined on diffusion-weighted imaging using low field MRI within 48 hours after clinical symptoms. Diffusion-weighted imaging was examined using line scan method. Twenty-four cases were cortical infarction, and twenty-two cases were perforating infarction. In five cases out of 51 cases, ischemic regions were not detected as abnormal high signal intensity area on diffusion-weighted imaging. Four cases of no abnormal detection were transient ischemic attack, and the other one was a perforating infarction. The earliest detection time in cortical infarction cases was 1 hour and 20 minutes. On the other hand, the earliest detection time in perforating infarction cases was 3 hours. Detective ability for acute cerebral infarction on diffusion-weighted imaging by low field MRI was depending on both size and lesion of infarction. That is to say, either small size or brain stem infarction was hard to detect. Thin slice and vertical slice examination for the infarction may improve to diagnose in low field MRI. Our conclusion is acute cerebral infarction was able to be diagnosed on diffusion-weighted imaging by low field as well as high field MRI.
Subject(s)
Cerebral Infarction/diagnosis , Magnetic Resonance Imaging/methods , Acute Disease , Aged , Aged, 80 and over , Female , Humans , Male , Middle AgedABSTRACT
The promoter region of the liver/bone/ kidney-type alkaline phosphatase gene was examined to define the cis-acting regulatory sequences and transcription factors responsible for its expression in hematopoietic cells. Transient transfection experiments revealed that regions deleted up to -154 base pairs upstream from the transcription initiation site had significant activities to induce bacterial chloramphenicol acetyltransferase gene. The shortest DNA fragment was found to contain three GC boxes in addition to a TATA box. Electrophoretic mobility shift assay and Southwestern analysis showed that Sp3 could bind to the fragment. Western blot analysis also detected Sp3 protein in eluate from the DNA probe mixed with the nuclear extracts. Through the use of Drosophila Schneider cells that lack the Sp1 family of transcription factors, Sp3 was shown to activate the basal promoter in a dose-dependent manner. When the amount of Sp3 was limited, the most proximal GC box was found to be critical for the basal promoter activity.
Subject(s)
Alkaline Phosphatase/genetics , DNA-Binding Proteins/physiology , Hematopoietic Stem Cells/enzymology , Promoter Regions, Genetic/genetics , Transcription Factors/physiology , Alkaline Phosphatase/metabolism , Animals , Base Sequence , Blotting, Western , Bone and Bones/enzymology , Cell Line , DNA/analysis , DNA/genetics , DNA/metabolism , DNA-Binding Proteins/analysis , DNA-Binding Proteins/metabolism , Digoxigenin , Drosophila melanogaster/genetics , Electrophoresis, Polyacrylamide Gel , Enzyme Activation , Gene Expression Regulation, Enzymologic/genetics , Hematopoietic Stem Cells/physiology , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Kidney/enzymology , Liver/enzymology , Molecular Sequence Data , Regulatory Sequences, Nucleic Acid , Sp3 Transcription Factor , TransfectionABSTRACT
We report a case of a 38-year-old female patient who developed facial cellulitis after cord-blood stem cell transplantation (CBT). The cellulitis was refractory to treatment with antibiotics and antifungal agents. Because facial cellulitis is rare after transplantation, its mechanism could not be determined exactly. On day 40 after CBT, a nurse with expertise in cosmetic surgery attended our rounds and correctly assumed that the patient had received cosmetic rhinoplasty. Although conventional x-rays of the head were normal, a computed tomographic (CT) scan of the brain disclosed the presence of a foreign body over the nasal dorsum. As a result, the patient's symptoms were diagnosed as facial cellulitis associated with foreign material that had been implanted at the time of cosmetic surgery. At a pretransplantation interview, the patient did not mention her history of rhinoplasty. Even after she was shown the head CT scans that revealed the presence of nasal implants, she denied that she had received rhinoplasty before CBT. Unless we realize that patients may have received cosmetic surgery before transplantation, it is difficult to make a diagnosis of infection associated with foreign implants. To our knowledge this is the first report after transplantation of infection associated with cosmetic surgery. Such infections should be included on the list of complications after bone marrow transplantation.
Subject(s)
Cellulitis/etiology , Facial Dermatoses/etiology , Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation/adverse effects , Rhinoplasty/adverse effects , Adult , Cellulitis/pathology , Facial Dermatoses/pathology , Female , Foreign-Body Reaction/etiology , Humans , Nose/microbiology , Nose/pathology , Surgical Wound Infection/chemically induced , Transplantation Conditioning/adverse effectsABSTRACT
To investigate whether granulocyte colony-stimulating factor (G-CSF) administration to donors before harvest may lighten the burden imposed on them and accelerate the bone marrow (BM) recovery, we administered 2 microgram/kg/d of G-CSF for five consecutive days before the marrow harvest. All of the donors tolerated the G-CSF administration well without severe adverse events. After 5 d of G-CSF treatment, CD34+ cells and granulocyte-macrophage colony-forming units (GM-CFU) in the donors' BM exceeded baseline values by 4.2-fold (range 0.71-316) and 1.6-fold (0.28-118) respectively. The concentration of total nucleated cells (x 107/ml) in the graft increased from 1.61 (0.95-3.23) to 2.44 (1.27-4.01). Although we collected 1020 ml of BM and obtained 1.50 x 1010 nucleated cells from unprimed donors, 940 ml of BM were sufficient to obtain 2.14 x 1010 nucleated cells from primed donors. However, G-CSF-primed BM did not shorten the time to tri-lineage engraftment and the duration of hospitalization compared with unprimed BM, although primed BM contained more CD34+ cells than baseline values. We consider that the advantages of BM priming are not the acceleration of BM recovery but rather the reduction of blood loss during BM harvesting.
Subject(s)
Bone Marrow Cells/cytology , Bone Marrow Transplantation , Granulocyte Colony-Stimulating Factor/pharmacology , Tissue Donors , Adolescent , Adult , Antigens, CD34/analysis , Blood Loss, Surgical/prevention & control , Bone Marrow Cells/drug effects , Cell Count , Cell Division/drug effects , Female , Graft vs Host Disease/pathology , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Humans , Male , Middle Aged , Recombinant Proteins , Stimulation, Chemical , Tissue and Organ Harvesting/methodsABSTRACT
Pulmonary recurrence of malignant lymphoma is a rare event after stem cell transplantation. We report here a 45-year-old male who was successfully diagnosed with relapsed pulmonary T-cell lymphoma using an RT-PCR method. Clonal expansion of T cells expressing identical TCR V-D-J junction size (Vbeta5-Jbeta1.5) was demonstrated in lymphocyte groups obtained from both bronchoalveolar lavage fluid at relapse, and paraffin embedded lymph node samples resected when he was first diagnosed with angioimmunoblastic T-cell lymphoma. This method provided evidence to diagnose relapsed pulmonary angioimmunoblastic T-cell lymphoma in its early phase.
Subject(s)
Hematopoietic Stem Cell Transplantation , Lung Neoplasms/diagnosis , Lung Neoplasms/metabolism , Lymphoma, T-Cell/diagnosis , Lymphoma, T-Cell/metabolism , Neoplasm Recurrence, Local/diagnosis , Receptors, Antigen, T-Cell, alpha-beta/metabolism , Bronchoalveolar Lavage Fluid/cytology , Humans , Lung Neoplasms/surgery , Lymph Nodes/metabolism , Lymph Nodes/pathology , Lymphocytes/metabolism , Lymphoma, T-Cell/surgery , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Prostaglandin (PG) D2 is the most abundant prostanoid produced in the central nervous system of mammals and has been implicated in the modulation of neural functions such as sleep induction, nociception, regulation of body temperature, and odor responses. We generated gene-knockout mice for lipocalin-type PGD2 synthase (L-PGDS) and found that the intrathecal administration of PGE2, an endogenous pain-producing substance, failed to elicit allodynia (touch-evoked pain), which is one typical phenomenon of neuropathic pain, whereas it evoked thermal hyperalgesia, in L-PGDS-/- mice. We also found that the allodynic response induced by the gamma-aminobutyric acid (GABA)A receptor antagonist bicuculline was selectively abolished in the L-PGDS-/- mice, among excitatory and inhibitory agents that induced allodynia in wild-type mice. Interestingly, simultaneous injection of a femtogram amount of PGD2 with PGE2 or bicuculline induced allodynia in L-PGDS-/- mice to the same extent as in wild-type mice. The PGE2- or bicuculline-evoked allodynia in wild-type and in PGD2-supplemented L-PGDS-/- mice was blocked by a PGD2 receptor antagonist given in a femtogram amount. These results reveal that endogenous PGD2 is essential for both PGE2- and bicuculline-induced allodynia.
Subject(s)
Anesthesia , Intramolecular Oxidoreductases/genetics , Pain/genetics , Animals , Bicuculline/pharmacology , Central Nervous System/physiopathology , Dinoprost/pharmacology , Dinoprostone/pharmacology , GABA Antagonists/pharmacology , Gene Targeting/methods , Hydantoins/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/physiopathology , Immunohistochemistry , Intramolecular Oxidoreductases/deficiency , Lipocalins , Mice , Mice, Knockout , Molecular Sequence Data , Pain/physiopathology , Prostaglandin D2/pharmacology , Receptors, Prostaglandin/antagonists & inhibitorsABSTRACT
To identify essential molecules capable of inducing terminal morphologic maturation and cell death of myeloid progenitor cells, we isolated cDNA clones by functional expression cloning using a library constructed from all-trans retinoic acid (ATRA)-treated human promyelocytic HL-60 cells. Clones which induced morphologic changes in HL-60 cells from blastic cells to mature neutrophilic granulocytes were selected. The isolated positive cDNA clone was demonstrated to encode an antisense RNA for cytochrome c oxidase/serine tRNA derived from a mitochondrial gene (MARCO). When MARCO was expressed in HL-60 cells with the lac switch system, blastic cell morphology became neutrophilic after 48-hour incubation with IPTG, and cell death was observed after 3 days. Also, high molecular weight DNA fragmentation was observed after 36 hours in culture. Similar results were observed using transformants from human K562 cells and CMK cells. RT-PCR analysis revealed that MARCO was transcribed in both ATRA and TNF-alpha systems, and also in human blood neutrophilic granulocytes. Following transfection with cytochrome c oxidase expression plasmids, TNF-alpha-induced high molecular weight DNA fragmentation in U937 cells and HL-60 cells was inhibited in these transformants. These results indicate that maturational changes in hematopoietic cells and the process of cell death may be induced by mitochondrial respiratory insufficiency, and also that the mitochondrial gene MARCO may be used as one of the candidates for gene supplementation therapy for the acute leukemias.
Subject(s)
Apoptosis/genetics , Electron Transport Complex IV/genetics , Hematopoietic Stem Cells/cytology , Mitochondria/genetics , RNA, Antisense/metabolism , Base Sequence , DNA, Complementary/isolation & purification , HL-60 Cells , Humans , Molecular Sequence Data , Polymerase Chain Reaction , Tumor Necrosis Factor-alpha/metabolismABSTRACT
We report on seven chronic myelogenous leukemia (CML) patients who received autologous bone marrow transplantation (ABMT) using bone marrow (BM) cells while at the chronic phase (CP) under the various treatments. Of the seven patients, four progressed to accelerated phase (AP) in 83-248 weeks after onset and three patients entered blastic crisis (BC) in 84-171 weeks after onset. All patients received high-dose chemoradiotherapy followed by infusion with 11.3 +/- 12.1 x 10(7) (average +/- S.D.) of bone marrow mononuclear cells (BM-MNCs)/kg IFN-alpha was resumed shortly after platelet recovery. Of the four patients in AP, one developed a recurrence of blastoma in 7 weeks, one progressed to second AP in 138 weeks after ABMT and two patients have survived the second CP for 159 and 330 weeks since ABMT, respectively. One of them achieved the complete disappearance of Ph1-positive metaphases for 33 weeks after ABMT. Of patients who received AMBT in BC, three relapsed within 8 weeks and died in 9, 17 and 58 weeks after ABMT, respectively. Hematological recovery was delayed in four patients. Therefore, we retrospectively re-evaluated the number of BM-MNCs collected through 50 procedures from 40 patients with CML-CP. The total MNCs obtained from 30 collections under IFN-alpha treatment was 27.4 +/- 30.9 x 10(8) cells (average +/- S.D.), being significantly lower than that obtained from 20 collections in pre-treatment state or with single chemotherapy other than IFN-alpha treatment (81.8 +/- 68.2 x 10(8) cells) (P < 0.005). The total number of MNCs correlated to white blood cell (WBC) count at BM collection (P < 0.01), which was also lower in the IFN-alpha(+) group than in the IFN-alpha(-) group (7.2 +/- 5.7 and 25.6 +/- 32.3 x 10(9)/l; P < 0.005). Our findings suggested that ABMT with the use of a sufficient number of progenitor cells might be helpful to CML patients in early AP and reach in extended periods of second CP. In addition, we suggest that BM collection is required before the start of IFN-alpha therapy because the total number of BM-MNCs correlated to the WBC count, which might be lower in IFN-alpha treatment.
Subject(s)
Antineoplastic Agents/therapeutic use , Bone Marrow Transplantation , Interferon-alpha/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Adolescent , Adult , Combined Modality Therapy , Female , Humans , Male , Retrospective Studies , Transplantation, AutologousABSTRACT
To investigate the role of NF-IL6 in vivo, we have generated NF-IL6 (-/-) mice by gene targeting. NF-IL6 (-/-) mice were highly susceptible to infection by Listeria monocytogenes. Electron microscopic observation revealed the escape of a larger number of pathogens from the phagosome to the cytoplasm in activated macrophages from NF-IL6 (-/-) mice. Furthermore, the tumor cytotoxicity of macrophages from NF-IL6 (-/-) mice was severely impaired. However, cytokines involved in macrophage activation, such as TNF and IFN gamma, were induced normally in NF-IL6 (-/-) mice. Nitric oxide (NO) formation was induced to a similar extent in macrophages from both wild-type and NF-IL6 (-/-) mice. These results demonstrate the crucial role of NF-IL6 in macrophage bactericidal and tumoricidal activities as well as the existence of a NO-independent mechanism of these activities. We also demonstrate that NF-IL6 is essential for the induction of G-CSF in macrophages and fibroblasts.
Subject(s)
Cytotoxicity, Immunologic , DNA-Binding Proteins/genetics , Listeria monocytogenes/immunology , Listeriosis/immunology , Macrophages, Peritoneal/physiology , Nuclear Proteins/genetics , Animals , Arginine/analogs & derivatives , Arginine/pharmacology , Base Sequence , Biological Assay , CCAAT-Enhancer-Binding Proteins , DNA Primers , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/physiology , Granulocyte Colony-Stimulating Factor/analysis , Granulocyte Colony-Stimulating Factor/biosynthesis , Hydrogen Peroxide/metabolism , Interferon-gamma/pharmacology , Interleukin-6/physiology , Macrophage Activation , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/immunology , Mice , Mice, Mutant Strains , Mice, Transgenic , Molecular Sequence Data , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/biosynthesis , Nuclear Proteins/biosynthesis , Nuclear Proteins/physiology , Polymerase Chain Reaction , Stem Cells , Superoxides/metabolism , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology , omega-N-MethylarginineABSTRACT
Recombinant human glycosylated G-CSF (rhG-CSF) may stimulate proliferation of myeloid leukemia cells and thereby increase their susceptibility to anti-cancer agents. By in vitro colony assay, the rhG-CSF-responsive NFS-60 leukemic cell clones are more effectively killed by Ara C in the presence of rhG-CSF than in the absence of rhG-CSF, while the killing of the rhG-CSF-unresponsive HL-60 cell clones is unaffected by rhG-CSF. Leukemia cell colony forming units (L-CFU) derived from most AML patients demonstrate similar results to those of the NFS-60 cell clone when treated in vitro. Encouraged by these in vitro results, we used rhG-CSF as a component of a conditioning regimen for 15 relapsed AML patients who were receiving allogeneic BMT. The patients were conditioned with total body irradiation (TBI) and high-dose Ara C. rhG-CSF was infused continuously at a dose of 5 micrograms/kg/day from 24 h before the beginning of TBI to the end of Ara C therapy. Proliferation of the leukemia cells in vivo in response to rhG-CSF was confirmed in 7 of 14 patients tested and the combined use of rhG-CSF had no additional adverse effects. After BMT, four patients died of non-leukemic causes and three patients had leukemic relapse: the other eight patients have remained disease-free for 200-1600 (median 417) days. The actuarial probabilities of relapse and disease-free survival (DFS) at 4.4 years after BMT were 43.2% and 41.7%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Bone Marrow Transplantation , Cytarabine/therapeutic use , Granulocyte Colony-Stimulating Factor/therapeutic use , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/therapy , Acute Disease , Adolescent , Adult , Combined Modality Therapy , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Glycosylation , Humans , In Vitro Techniques , Leukemia, Myeloid/pathology , Male , Pilot Projects , Recombinant Proteins/therapeutic use , Recurrence , Tumor Cells, Cultured , Whole-Body IrradiationABSTRACT
Introduction of interferon-alpha therapy to chronic myelogenous leukemia (CML) has improved the survival rate of CML patients compared with conventional busulfan therapy. There still, however, are some IFN-resistant cases. To improve the survival rate of these IFN-resistant cases, bone marrow transplantation (BMT) has been tried at the world wide level. In cases without any allogeneic donors, autologous BMT is another choice. We recently have proposed the flow chart therapy system to select the auto-BMT candidates in CML patients. This system, briefly, consists of (1) bone marrow collection as early stage of CML as possible, (2) IFN-alpha treatment with administration of weekly methotrexate or occasional use of hydroxyurea, (3) early detection of accelerated or blastic phase of CML by using scoring system, (4) conditioning regimens of auto-BMT for CML and (5) post-BMT follow-up with IFN-alpha. Following this system, we have initiated the treatment of CML cases. Our tentative results on one case favorable outcome including complete disappearance of Ph1 positive clone. However, there are several questions to be answered in the auto-BMT for CML, namely, (1) do we need to purge Ph1 progenitor cells or not, if yes, how? (2) does the long term use of IFN affect the bone marrow microenvironment resulting in graft failure? Although our preliminary results gave some answers on these questions, further clinical and basic studies are required to obtain higher survival rates in CML treatment.